ZSTK-474 is a small molecule inhibitor that belongs to the phosphoinositide 3-kinase (PI3K) family of enzymes. It is known for its potential use in cancer treatment due to its ability to target certain cancer cells and inhibit their growth.
Chemical name: 2-[1-(9H-purin-6-ylamino)ethyl]-3-(4-morpholinyl)-1H-indazole-5-carboxamide Molecular formula: C20H23N7O2 Formula weight: 393.45 g/mol CAS No: 475110-96-4
Top ten keywords from Google and Synonyms:
Health benefits of this product: ZSTK-474 has been shown to have anti-tumor activity by inhibiting the PI3K signaling pathway, which is frequently overactive in many types of cancers. This inhibition leads to the suppression of cell proliferation and the induction of apoptosis, or programmed cell death. Additionally, ZSTK-474 has been shown to sensitize cancer cells to other forms of chemotherapy, resulting in more effective cancer treatment.
Potential effects: Studies have shown that ZSTK-474 has potential therapeutic effects in various types of cancer, including breast cancer, ovarian cancer, and lung cancer. It has also been shown to have potential in treating neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.
Product mechanism: ZSTK-474 works by inhibiting the PI3K signaling pathway, which is frequently overactive in many types of cancer cells. This pathway is critical for cell growth and proliferation, and its dysregulation can lead to uncontrolled cell growth and tumor formation. By inhibiting this pathway, ZSTK-474 blocks the downstream activation of AKT and mTOR, which are key regulators of cell survival and growth. This leads to apoptosis, or programmed cell death, and the suppression of cancer cell growth.
Safety: As with any medication, safety is a concern when using ZSTK-474. Studies have shown that ZSTK-474 is generally well-tolerated and has a good safety profile. However, like other PI3K inhibitors, it can cause side effects such as diarrhea, nausea, vomiting, and fatigue. It is important to consult with a healthcare provider before using ZSTK-474 and to closely monitor any potential side effects.
Side effects: Some of the common side effects of ZSTK-474 include gastrointestinal symptoms such as diarrhea, nausea, vomiting, and abdominal pain. Other potential side effects include fatigue, headache, and rash. In rare cases, ZSTK-474 can cause serious side effects such as liver toxicity, so close monitoring is recommended.
Dosing information: ZSTK-474 is typically administered orally as a tablet. The optimal dose and duration of treatment will vary depending on the individual patient and the type of cancer being treated. It is important to follow dosing instructions carefully and to consult with a healthcare provider before beginning treatment with ZSTK-474.
Conclusion: ZSTK-474 is a promising small molecule inhibitor that has demonstrated potential in treating various types of cancer and neurodegenerative diseases. Its mechanism of action involves inhibiting the PI3K signaling pathway, which is frequently overactive in many types of cancer cells. Although it has a good safety profile, potential side effects must be closely monitored. Further research is needed to fully explore the therapeutic potential of ZSTK-474 and its applications in treating various diseases